Cost-Utility Analysis of Glucagon-Like Peptide-1 Agonists Compared with Dipeptidyl Peptidase-4 Inhibitors or Neutral Protamine Hagedorn Basal Insulin as Add-On to Metformin in Type 2 Diabetes in Sweden.

Research output: Contribution to journalArticle

Abstract

This study aimed to assess the costs and benefits of three alternative second-line treatment strategies for Swedish patients with type 2 diabetes mellitus (T2DM) who fail to reach glycated hemoglobin (HbA1c) ≤ 7% with metformin treatment alone: glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and neutral protamine Hagedorn (NPH) insulin.

Details

Authors
Organisations
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Endocrinology and Diabetes
Original languageEnglish
Pages (from-to)591-607
JournalDiabetes therapy : research, treatment and education of diabetes and related disorders
Volume5
Issue number2
Publication statusPublished - 2014
Publication categoryResearch
Peer-reviewedYes

Total downloads

No data available

Related research output

Aliasghar Ahmad Kiadaliri, 2014, Health Economics. 57 p.

Research output: ThesisDoctoral Thesis (compilation)

View all (1)